Forta Bio is a next-generation biotech company developing precision therapies that selectively eliminate disease-driving immune and cancer cells — without compromising healthy immunity.
Our proprietary cell targeting 6tdGO DNA platform uses a dual mechanism of action to directly disrupt telomeres in specific TERT+ cells while activating the body’s immune response. This approach is uniquely suited for treating aggressive cancers and autoimmune diseases.
We focus on high-burden, underserved conditions — particularly those affecting women and children — and pursue accelerated regulatory pathways.
Backed by validated science from City of Hope and led by a team with 7+ INDs, 30+ pharma deals, and multiple biotech exits, Forta Bio is on a mission to bring smarter, safer, and more targeted therapies to patients who need them most.
Company Details
- Employees
- 4
- Founded
- 2025
- Address
- San Francisco, Ca, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.forta.bio
- Keywords
- Biotech, Oligonucleotide Therapies, Autoimmune Diseases Therapies, Cancer Therapies, In-vivo Genetic, Targeted Medicine.
- HQ
- San Francisco, CA
Forta Bio Questions
Forta Bio's website is https://www.forta.bio
Forta Bio's LinkedIn profile is https://www.linkedin.com/company/fortabio
Forta Bio has
4 employees.
View email and phone details for 4
employees at Forta Bio.
Forta Bio's industry is
Biotechnology Research
Forta Bio's top competitors are
Duet Biotherapeutics,
Curemsd,
Glycologix,
Oncoseer Diagnostics, Inc.,
Altheia, Inc.,
S2 Health Partners Llc,
Precision Quantomics,
Superteam Poland,
Shup,
Helixomer Inc..
Forta Bio's categories are Biotechnology Research
Forta Bio's founding year is 2025
